ValiRx plc (VAL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ValiRx plc (VAL) has a cash flow conversion efficiency ratio of -0.179x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (£-700.73K ≈ $-941.02K USD) by net assets (£3.92 Million ≈ $5.26 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see VAL stock market capitalisation for the company's overall valuation and market capitalisation.
ValiRx plc - Cash Flow Conversion Efficiency Trend (2001–2024)
This chart illustrates how ValiRx plc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ValiRx plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ValiRx plc ranked by their cash flow conversion efficiency. Explore VAL cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
On The Beach Group PLC
LSE:OTB
|
0.335x |
|
Devernois SA
PA:ALDEV
|
0.102x |
|
Glacier Lake Resources Inc
V:GLI
|
0.010x |
|
QcX Gold Corp
V:QCX
|
-0.031x |
|
Commander Resources Ltd
V:CMD
|
-0.123x |
|
G-Tec Jainx Education Limited
NSE:GTECJAINX
|
N/A |
|
Kmc Properties ASA
OL:KMCP
|
0.039x |
|
FATHOM NICKEL INC.
F:6Q5
|
-0.086x |
Annual Cash Flow Conversion Efficiency for ValiRx plc (2001–2024)
The table below shows the annual cash flow conversion efficiency of ValiRx plc from 2001 to 2024. View ValiRx plc stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | £3.92 Million ≈ $5.26 Million |
£-1.58 Million ≈ $-2.13 Million |
-0.405x | +33.68% |
| 2023-12-31 | £2.90 Million ≈ $3.90 Million |
£-1.77 Million ≈ $-2.38 Million |
-0.610x | -36.39% |
| 2022-12-31 | £3.83 Million ≈ $5.14 Million |
£-1.71 Million ≈ $-2.30 Million |
-0.447x | -21.21% |
| 2021-12-31 | £3.41 Million ≈ $4.59 Million |
£-1.26 Million ≈ $-1.69 Million |
-0.369x | +8.12% |
| 2020-12-31 | £4.76 Million ≈ $6.39 Million |
£-1.91 Million ≈ $-2.57 Million |
-0.402x | +33.42% |
| 2019-12-31 | £2.22 Million ≈ $2.99 Million |
£-1.34 Million ≈ $-1.80 Million |
-0.604x | +45.45% |
| 2018-12-31 | £3.03 Million ≈ $4.07 Million |
£-3.35 Million ≈ $-4.50 Million |
-1.106x | -48.34% |
| 2017-12-31 | £3.15 Million ≈ $4.23 Million |
£-2.35 Million ≈ $-3.16 Million |
-0.746x | +58.08% |
| 2016-12-31 | £2.37 Million ≈ $3.18 Million |
£-4.22 Million ≈ $-5.66 Million |
-1.779x | -211.40% |
| 2015-12-31 | £4.53 Million ≈ $6.09 Million |
£-2.59 Million ≈ $-3.48 Million |
-0.571x | +47.02% |
| 2014-12-31 | £2.79 Million ≈ $3.74 Million |
£-3.01 Million ≈ $-4.04 Million |
-1.079x | -68.52% |
| 2013-12-31 | £3.23 Million ≈ $4.34 Million |
£-2.07 Million ≈ $-2.78 Million |
-0.640x | -62.79% |
| 2012-12-31 | £5.04 Million ≈ $6.76 Million |
£-1.98 Million ≈ $-2.66 Million |
-0.393x | -19.06% |
| 2011-12-31 | £4.42 Million ≈ $5.94 Million |
£-1.46 Million ≈ $-1.96 Million |
-0.330x | -32.96% |
| 2010-12-31 | £2.00 Million ≈ $2.68 Million |
£-496.00K ≈ $-666.08K |
-0.248x | +75.67% |
| 2009-12-31 | £907.00K ≈ $1.22 Million |
£-926.00K ≈ $-1.24 Million |
-1.021x | -76.42% |
| 2008-12-31 | £1.37 Million ≈ $1.84 Million |
£-794.00K ≈ $-1.07 Million |
-0.579x | -15.19% |
| 2007-12-31 | £1.67 Million ≈ $2.24 Million |
£-839.00K ≈ $-1.13 Million |
-0.502x | -2848.55% |
| 2006-12-31 | £2.69 Million ≈ $3.61 Million |
£-45.77K ≈ $-61.46K |
-0.017x | +95.01% |
| 2006-03-31 | £161.00K ≈ $216.21K |
£-55.00K ≈ $-73.86K |
-0.342x | -210.08% |
| 2005-12-31 | £-203.00K ≈ $-272.61K |
£-63.00K ≈ $-84.60K |
0.310x | -90.48% |
| 2004-12-31 | £-69.00K ≈ $-92.66K |
£-225.00K ≈ $-302.15K |
3.261x | +195.24% |
| 2003-12-31 | £67.00K ≈ $89.97K |
£74.00K ≈ $99.38K |
1.104x | +108.81% |
| 2002-12-31 | £-141.00K ≈ $-189.35K |
£1.77 Million ≈ $2.37 Million |
-12.539x | -759.53% |
| 2001-12-31 | £1.00 Million ≈ $1.35 Million |
£1.91 Million ≈ $2.56 Million |
1.901x | -- |
About ValiRx plc
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stag… Read more